胰腺导管腺癌的治疗研究进展

Research progress of treatment for pancreatic ductal adenocarcinoma

摘要:

胰腺导管腺癌（PDAC）是一种易发生微转移的恶性肿瘤，其早期缺乏明显症状，但经常侵犯周围正常组织。大部分患者在确诊时已处于晚期，其中局限性和转移性癌的5年生存率仅为23%和5%。如何提高PDAC患者的生存率、优化治疗方案和提高治愈率等是现今急需解决的问题。目前以手术为主的多学科诊治和个体化治疗模式成为研究热点，包括PDAC的发生机制、分期要素治疗、新辅助治疗和术后的监测治疗等。笔者就PDAC的各种治疗方法的研究进展进行综述。

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor that is prone to micrometastasis, lacks obvious symptoms in early stage, but often invades the surrounding healthy tissues. The majority of patients are found to be at an advanced stage at the time of diagnosis, the 5-year survival rates of those with localized cancer and metastatic cancer are only 23% and 5%, respectively. Therefore, how to improve the survival rate of PDAC patients, optimize the therapeutic schedule and increase the cure rate are currently urgent issues. At present, operation-based multidisciplinary treatment and individualized treatment mode have become the research focuses, which include the pathogenetic mechanism, staged treatment strategy, neoadjuvant therapy and postoperative monitoring of PDAC. The authors address the research progress of various treatment methods for PDAC.